Search
EHA Endorsement of ESMO Clinical Practice Guidelines on Hodgkin Lymphoma
EHA and ESMO agreed to collaborate in the production of European Guidelines for different hematological malignancies. For the second workshop in the series participants joined us for the EHA Endorsement of ESMO Clinical Practice Guidelines on Hodgkin Lymphoma.
Read moreHighlights of Past EHA (HOPE) Latin America (LA) 2022 - report
November 17-19, 2022 – Barranquilla, Colombia
Meeting chairs:
D McLornan, Vice-Chair Global Outreach Program Committee, European Hematology Association (EHA)
V Abello Polo, President, Asociación Colombiana de Hematología y Oncología (ACHO)
This year, the HOPE LA meeting was held in collaboration with the Asociación Colombiana…
Registration & accommodation
Register here
Individual RegistrationRegistration fee includes:
Access to the scientific and educational sessions of the meeting. Digital meeting materials including the program and abstract book. Networking opportunities during breaks, receptions and dinners.
Meeting program
Friday, April 25 - EHA-Balkan Hematology Day 202509:00 - 10:10 CEST Opening remarks & special lecture
Welcome of participants
Dimitar Efremov (Italy)
Welcome and introduction of meeting program
Irina Panovska-Stavridis (North Macedonia)
EHA and History of Balkan Hematology Day
Gianluca Gaidano (Italy)
History of the Balkan Hematology…
HARMONY: Big data for better and faster treatment
HARMONY Alliance: A European Network of Excellence for Big Data in Hematology - Enabling Better and Faster Treatment based on Big Data technologies
Despite data being a key driver for modern evidence-based medicine, we have been struggling with the same challenge for…
Selected EMA news
March 2025New medicines recommended for approval
Lynozyfic (linvoseltamab)
Treatment of refractory multiple myeloma (a cancer of the bone marrow)
New information on approved medicines
Calquence (acalabrutinib) - new indication
Treatment of blood cancer
Columvi (glofitamab) - new indication
Treatment of blood cancer
Darzalex (daratumumab) - change of indication
Treatment…
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- »